Publisher's Note: FiercePharmaAsia is now weekly

Starting this week, we’ll be changing the frequency of FiercePharmaAsia to a once-weekly report. Moving forward, you will receive your newsletter in your inbox once per week on Tuesdays.  Your next newsletter should hit your inbox on Tuesday, August 23rd.

We have a few other changes to the newsletter that we are looking forward to. We are moving up our deadline to get the news to you faster and more in line with your local time zone. We’ll also be covering Asia news across all of the publications so follow our coverage on the website and in our other Life Sciences publications.

As always, thank you for being a part of the FiercePharma community. Your feedback is always welcome so please reach out any time with questions, comments, or suggestions on how we can do better. Rebecca Willumson (email | Twitter)

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Suggested Articles

Glenmark hopes to raise cash from selling drugs outside of its focus therapeutic areas and from finding new investors for its API and innovation spinoffs.

Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.

There are five or six potential deals similar to Takeda's mooted European sale Stada could go after, CEO Peter Goldschmidt said.